|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niu ZS, Niu XJ and Wang M: Management of
hepatocellular carcinoma: Predictive value of immunohistochemical
markers for postoperative survival. World J Hepatol. 7:7–27. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanash SM, Baik CS and Kallioniemi O:
Emerging molecular biomarkers - blood-based strategies to detect
and monitor cancer. Nat Rev Clin Oncol. 8:142–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stassen M, Schmitt E and Bopp T: From
interleukin-9 to T helper 9 cells. Ann N Y Acad Sci. 1247:56–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Renauld JC, Druez C, Kermouni A, Houssiau
F, Uyttenhove C, Van Roost E and Van Snick J: Expression cloning of
the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad
Sci USA. 89:5690–5694. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noelle RJ and Nowak EC: Cellular sources
and immune functions of interleukin-9. Nat Rev Immunol. 10:683–687.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goswami R and Kaplan MH: A brief history
of IL-9. J Immunol. 186:3283–3288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Demoulin JB and Renauld JC: Interleukin 9
and its receptor: An overview of structure and function. Int Rev
Immunol. 16:345–364. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Druez C, Coulie P, Uyttenhove C and Van
Snick J: Functional and biochemical characterization of mouse
P40/IL-9 receptors. J Immunol. 145:2494–2499. 1990.PubMed/NCBI
|
|
11
|
Demoulin JB, Uyttenhove C, Van Roost E,
DeLestré B, Donckers D, Van Snick J and Renauld JC: A single
tyrosine of the interleukin-9 (IL-9) receptor is required for STAT
activation, antiapoptotic activity, and growth regulation by IL-9.
Mol Cell Biol. 16:4710–4716. 1996.PubMed/NCBI
|
|
12
|
Demoulin JB, Louahed J, Dumoutier L,
Stevens M and Renauld JC: MAP kinase activation by interleukin-9 in
lymphoid and mast cell lines. Oncogene. 22:1763–1770. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamasaki A, Saleh A, Koussih L, Muro S,
Halayko AJ and Gounni AS: IL-9 induces CCL11 expression via STAT3
signalling in human airway smooth muscle cells. PLoS One.
5:e91782010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jäger A, Dardalhon V, Sobel RA, Bettelli E
and Kuchroo VK: Th1, Th17, and Th9 effector cells induce
experimental autoimmune encephalomyelitis with different
pathological phenotypes. J Immunol. 183:7169–7177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forbes EE, Groschwitz K, Abonia JP, Brandt
EB, Cohen E, Blanchard C, Ahrens R, Seidu L, McKenzie A, Strait R,
et al: IL-9- and mast cell-mediated intestinal permeability
predisposes to oral antigen hypersensitivity. J Exp Med.
205:897–913. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sismanopoulos N, Delivanis DA,
Alysandratos KD, Angelidou A, Vasiadi M, Therianou A and
Theoharides TC: IL-9 induces VEGF secretion from human mast cells
and IL-9/IL-9 receptor genes are overexpressed in atopic
dermatitis. PLoS One. 7:e332712012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kearley J, Erjefalt JS, Andersson C,
Benjamin E, Jones CP, Robichaud A, Pegorier S, Brewah Y, Burwell
TJ, Bjermer L, et al: IL-9 governs allergen-induced mast cell
numbers in the lung and chronic remodeling of the airways. Am J
Respir Crit Care Med. 183:865–875. 2011. View Article : Google Scholar
|
|
18
|
Chen N, Lu K, Li P, Lv X and Wang X:
Overexpression of IL-9 induced by STAT6 activation promotes the
pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp
Pathol. 7:2319–2323. 2014.PubMed/NCBI
|
|
19
|
Shang Y, Kakinuma S, Nishimura M,
Kobayashi Y, Nagata K and Shimada Y: Interleukin-9 receptor gene is
transcriptionally regulated by nucleolin in T-cell lymphoma cells.
Mol Carcinog. 51:619–627. 2012. View
Article : Google Scholar
|
|
20
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi JY, Gao Q, Wang ZC, Zhou J, Wang XY,
Min ZH, Shi YH, Shi GM, Ding ZB, Ke AW, et al: Margin-infiltrating
CD20(+) B cells display an atypical memory phenotype and correlate
with favorable prognosis in hepatocellular carcinoma. Clin Cancer
Res. 19:5994–6005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vitale A, Morales RR, Zanus G, Farinati F,
Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo
MA, et al: Italian Liver Cancer group: Barcelona Clinic Liver
Cancer staging and transplant survival benefit for patients with
hepatocellular carcinoma: A multicentre, cohort study. Lancet
Oncol. 12:654–662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH,
Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, et al: CXCR6 upregulation
contributes to a proinflammatory tumor microenvironment that drives
metastasis and poor patient outcomes in hepatocellular carcinoma.
Cancer Res. 72:3546–3556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shang Y, Kakinuma S, Amasaki Y, Nishimura
M, Kobayashi Y and Shimada Y: Aberrant activation of interleukin-9
receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo
in susceptible B6 and resistant C3H mice. In Vivo. 22:713–720.
2008.
|
|
25
|
Chen N and Wang X: Role of IL-9 and STATs
in hematological malignancies (Review). Oncol Lett. 7:602–610.
2014.PubMed/NCBI
|
|
26
|
Barata JT, Keenan TD, Silva A, Nadler LM,
Boussiotis VA and Cardoso AA: Common gamma chain-signaling
cytokines promote proliferation of T-cell acute lymphoblastic
leukemia. Haematologica. 89:1459–1467. 2004.PubMed/NCBI
|
|
27
|
Glimelius I, Edström A, Amini RM, Fischer
M, Nilsson G, Sundström C, Enblad G and Molin D: IL-9 expression
contributes to the cellular composition in Hodgkin lymphoma. Eur J
Haematol. 76:278–283. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gruss HJ, Brach MA, Drexler HG, Bross KJ
and Herrmann F: Interleukin 9 is expressed by primary and cultured
Hodgkin and Reed-Sternberg cells. Cancer Res. 52:1026–1031.
1992.PubMed/NCBI
|
|
29
|
Nagato T, Kobayashi H, Kishibe K, Takahara
M, Ogino T, Ishii H, Oikawa K, Aoki N, Sato K, Kimura S, et al:
Expression of interleukin-9 in nasal natural killer/T-cell lymphoma
cell lines and patients. Clin Cancer Res. 11:8250–8257. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
